Cocrystal Pharma, Inc.

Bristol-myers Squibb Pharma Company

Other

Cocrystal, Discovery, Inc.

Merck Sharp + Dohme Corp.

Neumedics

Irina C Jacobson

Ruth Richmond Wexler

Sam S K Lee

Mimi Lifen Quan

Edward A Kesicki

Michael David Feese

Iain W Duncan

William D Schwieterman

Sam S Lee

Carl G Osborne

Wang Shen

Patrick Y S Lam

Xiaoling Zheng

Biing Yuan Lin

Donald J P Pinto

John Matthew Fevig

Joanne M Smallheer

Robert A Galemmo, Jr

Charles G Clark

Qi Han

Shuaige Wang

Renhau Li

Yun-Long Li

Jennifer X Qiao

Suanne Nakajima

Liang Mao

Emiliano J Sanchez

Tianjing Zhao

Hong Xiao

Sam Lee

Sam Sk Lee

Provided herein are compounds of Formula A, B or C that can inhibit the replication of influenza viruses, reduce the amount of influenza viruses, and/or treat influenza.

Pyrrolo[2,3-B]pyridin derivatives as inhibitors of influenza virus replication

Provided herein are combinations of compounds that can inhibit the replication of influenza viruses, reduce the amount of influenza viruses, and/or treat influenza.

Combinations of inhibitors of influenza virus replication

Provided herein are compositions of an antiviral therapeutic to treat influenza suitable for administration via inhalation.

Formulations of influenza therapeutics

Provided herein are compounds that can inhibit the replication of influenza viruses, reduce the amount of influenza viruses, and/or treat influenza. (I)

Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication

Disclosed herein are combination therapies for use in the treatment or prevention of HCV by administering Compound A and a second HCV inhibitor.

Combination therapy for treatment of HCV

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient a safe and effective amount of a compound represented by any of Formulas I-III, or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a safe and effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle. 

Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication

The present invention provides, among other things, compounds represented by the general Formula I: (I) and pharmaceutically acceptable salts thereof, wherein L and A (and further substituents) are as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection. 

Inhibitors of Hepatitis C virus polymerase

Inhibitors of hepatitis C virus polymerase

The present invention provides, among other things, compounds represented by the general Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, R, and Rare as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection. 

The present disclosure is directed to compositions and methods which utilize the tetracycline scaffold, preferably the scaffold of tetracycline or minocycline, and which significantly lack antibiotic activity. The compounds have neuroprotective attributes without interfering with the drugs capacity to pass through the blood brain barrier. These compounds have neuroprotective activity because of their inhibition of neuronal cell cycle progression. The compounds are characterized in part by a fifth ring joining positions 9 and 10.

Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits

The present invention provides, among other things, compounds represented by the general Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, R, R, R, and Rare as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection.

Growing community of inventors

Sammamish, WA, United States of America

Irina C Jacobson